{"entity":{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","aka":["Avistone Biotechnology Co., Ltd."],"tldr":"Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.","summary":"Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.avistonebio.com"},{"label":"ClinicalTrials.gov: trials led by Avistone Biotechnology","url":"https://clinicaltrials.gov/search?lead=Avistone%20Biotechnology%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06343064","nct06574347","nct07538804","nct06015503","nct07336732"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.avistonebio.com","founded":2012,"stage":"growth","investors":[],"funding":[]},"route":"/companies/avistone-biotechnology/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"trial":[{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct06015503/"},{"id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/"},{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/"},{"id":"nct07336732","kind":"trial","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","route":"/trials/nct07336732/"},{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/"},{"id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/"},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/"},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/"},{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/"}],"company":[{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/"}]}}